FPRX - Five Prime Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.37
-0.13 (-2.36%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.59
Open5.53
Bid5.35 x 3200
Ask0.00 x 800
Day's Range5.32 - 5.55
52 Week Range5.32 - 16.36
Volume199,058
Avg. Volume496,939
Market Cap193.656M
Beta (3Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-4.49
Earnings DateAug 3, 2017 - Aug 7, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.14
Trade prices are not sourced from all markets
  • Estimating The Fair Value Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX)
    Simply Wall St.29 days ago

    Estimating The Fair Value Of Five Prime Therapeutics, Inc. (NASDAQ:FPRX)

    How far off is Five Prime Therapeutics, Inc. (NASDAQ:FPRX) from its intrinsic value? Using the most recent financial...

  • Business Wirelast month

    Five Prime Therapeutics Appoints Lori Lyons-Williams to its Board of Directors

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Lori Lyons-Williams to its Board of Directors. Ms. Lyons-Williams is an industry leader with 20 years of experience launching and commercializing innovative pharmaceutical products. “We welcome Lori to our board and look forward to her contributions as we continue to build Five Prime by advancing our differentiated clinical pipeline, leveraging our discovery platform, and collaborating with our strategic alliance partners,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics.

  • Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy?
    Insider Monkeylast month

    Is Five Prime Therapeutics Inc (FPRX) A Good Stock To Buy?

    Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]

  • Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session
    Zackslast month

    Five Prime Therapeutics (FPRX) Looks Good: Stock Adds 9.2% in Session

    Five Prime Therapeutics (FPRX) shares rose more than 9% in the last trading session, amid huge volumes.

  • Markitlast month

    See what the IHS Markit Score report has to say about Five Prime Therapeutics Inc.

    Five Prime Therapeutics Inc NASDAQ/NGS:FPRXView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for FPRX with fewer than 5% of shares on loan. Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on June 14. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding FPRX is favorable, with net inflows of $2.40 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Business Wirelast month

    Five Prime Therapeutics Announces the Departure of Dr. Sheila Gujrathi From its Board of Directors

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the departure of Dr. Sheila Gujrathi from the company’s board of directors. Dr. Gujrathi has served as a board member of Five Prime since December 2015 and is stepping down from the board to focus on her role as President and Chief Executive Officer of Gossamer Bio, Inc., a biopharmaceutical company that she co-founded in 2017 and that completed its initial public offering in February 2019.

  • Business Wirelast month

    Five Prime Therapeutics to Present at Two Upcoming Healthcare Conferences

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics today ann

  • Business Wire2 months ago

    Five Prime Therapeutics Presents Monotherapy Data From the Phase 1a/1b Trial of FPA150 in Patients With Advanced Solid Tumors at the 2019 ASCO Annual Meeting

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today presented monotherapy data from the dose escalation portion of the Phase 1a/1b clinical trial of FPA150 in patients with advanced solid tumors. The data are the first presentation of FPA150 results and include safety and pharmacokinetics results from the Phase 1a monotherapy dose escalation portion of the study. The Phase 1a monotherapy portion of the study is being conducted in patients with advanced solid tumors, and the Phase 1b monotherapy expansion is enrolling patients with breast, ovarian and endometrial tumors that overexpress B7-H4.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of FPRX earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 Five Prime Therapeutics Inc Earnings Call

  • Business Wire2 months ago

    Five Prime Therapeutics Appoints Carol Schafer to its Board of Directors

    Five Prime Therapeutics, Inc. (FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced the appointment of Carol Schafer to its Board of Directors. Ms. Schafer is an industry leader with more than 25 years of investment banking and equity capital markets experience in the biotechnology sector. “We welcome Carol to our board and look forward to her contributions as we continue to build Five Prime by advancing our differentiated clinical pipeline, leveraging our discovery platform, and collaborating with our strategic alliance partners,” said Aron Knickerbocker, Chief Executive Officer of Five Prime Therapeutics.

  • Business Wire2 months ago

    Five Prime Therapeutics Announces FPA150 Poster Presentation at the 2019 ASCO Annual Meeting

    – Phase 1a/1b Study of First-in-class B7-H4 Antibody as Monotherapy in Patients with Advanced Solid Tumors –

  • Five Prime Therapeutics (FPRX) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Five Prime Therapeutics (FPRX) Q1 2019 Earnings Call Transcript

    FPRX earnings call for the period ending March 31, 2019.

  • Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates
    Zacks3 months ago

    Five Prime Therapeutics (FPRX) Reports Q1 Loss, Misses Revenue Estimates

    Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 4.67% and -6.36%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press3 months ago

    Five Prime Therapeutics: 1Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.02. The results topped Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...

  • Business Wire3 months ago

    Five Prime Therapeutics Reports First Quarter 2019 Results

    Five Prime Therapeutics, Inc.  , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced its results for the first quarter and provided an update on the company’s recent activities.

  • Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline
    Zacks3 months ago

    Earnings Preview: Five Prime Therapeutics (FPRX) Q1 Earnings Expected to Decline

    Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • American City Business Journals3 months ago

    Can 'synthetic lethality' and deep experience propel this cancer-fighting biotech's $70M IPO?

    This Peninsula drug developer has four preclinical drugs aimed at triggering a process that it believes will kill cancer cells with genetic mutations.

  • Business Wire3 months ago

    Five Prime Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on May 8

    Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, will report its first quarter 2019 financial results on Wednesday, May 8, 2019, after the U.S. financial markets close.

  • What Should You Know About Five Prime Therapeutics, Inc.'s (NASDAQ:FPRX) Earnings Trajectory?
    Simply Wall St.3 months ago

    What Should You Know About Five Prime Therapeutics, Inc.'s (NASDAQ:FPRX) Earnings Trajectory?

    In December 2018, Five Prime Therapeutics, Inc. (NASDAQ:FPRX) released its latest earnings announcement, which showed company earnings became less negative compared to the previous year's level - gre...

  • Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more
    American City Business Journals4 months ago

    Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more

    How Genentech — with the help of a $1.7 billion merger — is breaking new ground in cancer … and more in our Health Care Digest.